Climb Bio (NASDAQ: CLYM) SVP Finance awarded 100,000 stock options at $3.81

Rhea-AI Filing Summary

Climb Bio, Inc. reported that Senior Vice President, Finance Cindy Driscoll received a grant of stock options. On January 6, 2026, she was awarded a stock option to buy 100,000 shares of common stock at an exercise price of $3.81 per share.

According to the grant terms, 25% of the option shares vest on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments through January 6, 2030, as long as she continues in service. Following this grant, she beneficially owns 100,000 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Driscoll Cindy

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MA 02481

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.81	01/06/2026		A		100,000		(1)	01/05/2036	Common Stock	100,000	$0.00	100,000	D

Explanation of Responses:

1. This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.

	/s/ Chandra Adams, as Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Climb Bio (CLYM) disclose in this Form 4?

The company disclosed that Senior Vice President, Finance Cindy Driscoll received a grant of 100,000 stock options to buy Climb Bio common stock.

What is the exercise price of Cindy Driscoll’s new Climb Bio (CLYM) stock options?

The stock option granted to Cindy Driscoll on January 6, 2026 carries an exercise price of $3.81 per share for Climb Bio common stock.

How many Climb Bio (CLYM) options does Cindy Driscoll own after this transaction?

After the reported grant, Cindy Driscoll beneficially owns 100,000 stock options for Climb Bio common stock, held directly.

What is the vesting schedule for Cindy Driscoll’s Climb Bio (CLYM) stock option grant?

The option vests as follows: 25% of the shares vest on the first anniversary of the January 6, 2026 grant date, and the remaining 75% vest in 36 equal monthly installments through January 6, 2030, subject to her continued service.

When do Cindy Driscoll’s Climb Bio (CLYM) options expire?

The stock option granted to Cindy Driscoll on January 6, 2026 is scheduled to expire on January 5, 2036.

What is Cindy Driscoll’s role at Climb Bio (CLYM)?

Cindy Driscoll is reported as an officer of Climb Bio, serving as Senior Vice President, Finance.